Kelt - the combo trial with the pfizer chemo drug either starts from scratch, with minimal doses in combo building up, or waits till kevetrin no longer considered trial/unapproved agent - which could mean waiting quite a while. Since fda involved here, a single ph1 open toxicity trial won't help them much. Efficacy is being looked at in this trial, but only ph11 to 111 trial is considered valid efficacy data by fda. (they do use evidence of phI efficacy to designate rapid path which I expect Kevetrin to get).

If kevetrin appears to be stand alone tx - Pfizer will move in to buy asap. then they will do ph11/111 trials on both singular and combo. On completion of successful concurrent singular and combo trials, Pfizer would own cancer therapy worldwide. They would have lead agent proven effective as stand alone and proven safe in combo with common chemo agent. The numbers would be mindboggling.